These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 31194979)

  • 21. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.
    Plevris N; Lyons M; Jenkinson PW; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Shand AG; Din S; Arnott ID; Jones GR; Lees CW
    Inflamm Bowel Dis; 2019 May; 25(6):1036-1043. PubMed ID: 30335139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
    Vande Casteele N; Baert F; Bian S; Dreesen E; Compernolle G; Van Assche G; Ferrante M; Vermeire S; Gils A
    J Crohns Colitis; 2019 Sep; 13(10):1248-1256. PubMed ID: 30820530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
    Mazor Y; Almog R; Kopylov U; Ben Hur D; Blatt A; Dahan A; Waterman M; Ben-Horin S; Chowers Y
    Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
    Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
    Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T;
    J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
    Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
    Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease.
    Zittan E; Steinhart AH; Goldstein P; Milgrom R; Gralnek IM; Silverberg MS
    Clin Transl Gastroenterol; 2021 Oct; 12(10):e00401. PubMed ID: 34613952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
    Ward MG; Thwaites PA; Beswick L; Hogg J; Rosella G; Van Langenberg D; Reynolds J; Gibson PR; Sparrow MP
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1135-1145. PubMed ID: 28239869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
    Billioud V; Sandborn WJ; Peyrin-Biroulet L
    Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Lo Pumo S; Brunacci M; De Bortoli N; Jain A; Tolone S; Savarino E
    Dig Liver Dis; 2018 May; 50(5):452-456. PubMed ID: 29274766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
    Gonczi L; Vegh Z; Golovics PA; Rutka M; Gecse KB; Bor R; Farkas K; Szamosi T; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Papp M; Patai Á; Salamon Á; Tóth GT; Vincze Á; Biro E; Lovasz BD; Kurti Z; Szepes Z; Molnár T; Lakatos PL
    J Crohns Colitis; 2017 Jun; 11(6):697-705. PubMed ID: 27838610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
    Merras-Salmio L; Kolho KL
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.